Psychiatry and Neurology, Neurology · Las Vegas, NV
NPI
1033408679
Since 2011
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
0
Medicare group memberships
Hospitals
1
Hospital affiliations
9975 S Eastern Ave Ste 130
Las Vegas, NV, 89183
Phone (702) 808-2650
Medicare paid, 2024
$96K
1,281 services
Medicare patients, 2024
491
Average age 73
Drug cost, 2024
$9.7M
8,979 prescriptions
Company payments, 2025
$17K
From 16 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Charles E Kamen was code 99214 (office e&m - established), 362 times for 229 patients. In total Charles E Kamen billed 1,281 services in 27 codes, and Medicare paid $96K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-06-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 362 | 229 | $85.19 | $31K |
| 99213 Office E&M - Established | Office | 209 | 158 | $67.56 | $14K |
| 99233 Hospital E&M - Subsequent | Facility | 161 | 90 | $89.91 | $14K |
| 99204 Office E&M - New | Office | 100 | 100 | $111.76 | $11K |
| 95874 Musculoskeletal | Office | 37 | 20 | $53.94 | $1,996 |
| 95816 Neurologic | Facility | 35 | 35 | $43.29 | $1,515 |
| 64616 Musculoskeletal | Office | 33 | 19 | $149.90 | $4,947 |
| 99223 Hospital E&M - Initial | Facility | 23 | 23 | $132.42 | $3,046 |
| 99222 Hospital E&M - Initial | Facility | 15 | 15 | $100.10 | $1,502 |
By year: 2022 $66K for 717 services; 2023 $104K for 1,292 services; 2024 $96K for 1,281 services.
Medicare prescription drug claims, 2024
In 2024, the drug Charles E Kamen prescribed most often to Medicare patients was Carbidopa-Levodopa (Carbidopa/Levodopa), with 2,534 prescriptions and refills. In total Charles E Kamen wrote 8,979 Medicare prescriptions that cost $9.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carbidopa-Levodopa Carbidopa/Levodopa | 2,534 | 4,284 | 650 | $42K |
| Carbidopa-Levodopa Er Carbidopa/Levodopa | 1,101 | 2,020 | 296 | $26K |
| Escitalopram Oxalate Generic | 678 | 1,095 | 160 | $3,875 |
| Primidone Generic | 572 | 1,023 | 139 | $9,152 |
| Nuplazid Pimavanserin Tartrate | 488 | 488 | 82 | $2.4M |
| Ingrezza Valbenazine Tosylate | 360 | 370 | 53 | $3.0M |
| Rytary Carbidopa/Levodopa | 223 | 273 | 40 | $229K |
| Donepezil Hcl Generic | 215 | 466 | 57 | $1,522 |
| Gabapentin Generic | 209 | 263 | 49 | $3,901 |
| Propranolol Hcl Generic | 172 | 315 | 46 | $3,183 |
| Austedo Xr Deutetrabenazine | 135 | 137 | 22 | $2.0M |
| Clonazepam Generic | 131 | 135 | 45 | $763 |
| Levetiracetam Generic | 129 | 223 | 38 | $1,968 |
| Rasagiline Mesylate Generic | 110 | 177 | 29 | $15K |
| Memantine Hcl Generic | 105 | 214 | 26 | $1,258 |
Brand drugs: 1,862 claims; generic drugs: 7,117 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Charles E Kamen $17K ($17K in general payments such as food, travel and fees) from 16 companies. The largest payer was Teva Pharmaceuticals USA, Inc. with $14K.
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. TEVA | 15 | $14K |
| ACADIA Pharmaceuticals Inc ACAD | 54 | $716 |
| Abbvie Inc. ABBV | 31 | $625 |
| Neurocrine BioSciences, Inc. NBIX | 40 | $385 |
| Medtronic, Inc. MDT | 2 | $325 |
| Boston Scientific Corporation BSX | 3 | $245 |
| Pfizer Inc. PFE | 10 | $199 |
| Abbott Laboratories ABT | 1 | $151 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $97.5 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 2 | $52.24 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.